Page 10 - Gates-AnnualReport-2019
P. 10

where the potential for impact from lab bench to bedside has the most promise and speed. Current areas of focus include the following:
Cardiology – Gates Center researchers investigate regenera- tive solutions to heart disease, including the 50 percent of heart attack cases that result in heart failure. One potential treatment is exploring a method for converting cardiac fibro- blasts into new heart muscle cells.
Ehlers-Danlos Syndrome – The Gates Center is the research arm of the Ehlers-Danlos Center of Excellence, created in partnership with Children’s Hospital Colorado and the Dean of the School of Medicine John Reilly, Jr., M.D., and dedicated to moving bold research ideas from the lab into the clinic to deliver the finest care for people living with this rare group of connective tissue disorders.
Epidermolysis Bullosa – World-leading research into the development of a cure for this devastating, inherited group of skin diseases is anchored at the Gates Center, which helps lead a consortium including University of Colorado Anschutz Medical Campus, Stanford University School of Medicine and Columbia University Medical Center.
Induced Pluripotent Stem (iPS) Cells – The Gates Center is an international pioneer in launching multi-dimensional research projects using induced pluripotent stem cells (iPSCs) with its unique, safe and efficient combined gene editing and cell reprogramming approach that raises hopes for future clinical trials and potential cures for critical illnesses.
Oncology – The Gates Center and the Gates Biomanufacturing Facility are key to revolutionary advances in CAR-T cell treatment for cancer developed by Dr. Terry Fry, M.D., and others. Advances in CAR-T and other materials are already improving patient lives in previously hopeless cases.
Ophthalmology – The promise and wonder of regenerative medicine is evident in Gates Center member labs where
researchers are growing new retinas in the CellSight laboratories to potentially reverse loss of sight and develop new therapies for millions of Americans suffering from macular degeneration and inherited retinal diseases.
Orthopedics – While the public hears misleading marketing claims about stem cells and joint repair, Gates Center researchers are conducting gold-standard clinical trials measuring the effectiveness of patient treatments and developing new scaffolds for joint and limb repair through 3D printing and cartilage regeneration.
Wound Healing – Gates Center members are producing groundbreaking results through various investigations, testing potential treatments that could speed tissue regeneration in debilitating skin wounds, reducing the chronic inflammation suffered by diabetes patients and treating side effects from radiation and chemotherapy.
Dennis Roop, Ph.D., recruited from the Baylor College of Medicine in 2007, is the Center Director and coordinates a talented array of 118 multi-institutional researchers from the Anschutz Medical Campus, CU Boulder, CU Denver, Colorado State University, Colorado School of Mines and National Jewish Health, as well as private industry. The Gates Advisory Board, comprised of community leaders and clinicians, provides counsel and additional support [see page 6-7].
Key to the success of the Gates Center is the partnership with the Gates Biomanufacturing Facility, a state-of-the-art manufacturing facility that works with on and off-campus investigators to translate innovative research discoveries into safe and effective cell therapy and protein biologic products for human clinical trials. The GBF operates under FDA “Good Manufacturing Practice” guidelines with a trained staff of more than 40 people within a 20,000 sq. ft. facility. The GBF has proven essential in engagement of research talent present on the Anschutz Medical Campus as well as in talent recruitment nationwide.
 Regenerative medicine includes research into the uses of adult stem cells, which can be reprogrammed into embryonic-like stem cells and then differentiated into virtually any cell type in the body. These core tools are referred to as induced Pluripotent Stem Cells (iPSCs). The long-term goal is to return iPSC-derived adult stem cells to the patient from whom they were derived in order to regenerate cells, organs and key bodily functions. Other research includes production and manipulation of key proteins in the body to fight or correct disease, and the alteration of a patient’s own T cells to produce CAR-T cells for immunotherapy to combat cancer.
10 Gates Center for Regenerative Medicine
 




















































































   8   9   10   11   12